Clinical Trial Update: The Efficacy and Safety of ITF2357 in AIS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ITF2357 (givinostat) for autoinflammatory syndromes, including Hyper-IgD syndrome, TNF receptor-associated periodic syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyper-igd Syndrome
• Schnitzler Syndrome
• Tnf Receptor-associated Periodic Syndrome

Drugs mentioned

• ITF2357 (givinostat) (givinostat)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Autoinflammatory Syndromes, HIDS | Phase 2 | Status: UNKNOWN